MantleBio
DefunctYC S23Founded 2023 · 7 employees · 4 known investors
MantleBio provides a data management and analytics platform designed for biotech researchers and scientific teams. The platform integrates biological data, enables advanced bioinformatics analysis, and accelerates drug development and genomics research workflows.
Also known as DryBox Bio
Founders & leadership· Y Combinator alumni (S23)
MantleBio was founded in 2023 by Emily Damato and Madeline Schade.
ED
Emily Damatoin𝕏CEO, Co-Founder2023–2025She previously held software development roles at GRAIL, Arsenal Bio, and The Broad Institute, and holds degrees in computer science and biology from MIT.
MS
Madeline Schadein𝕏CTO, Co-Founder2023–2025She previously held software engineering roles at Google, Arsenal Bio, and GRAIL.
Investors · 4
Competitors · 6
by search overlap
Manifold7 shared keywordsManifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.
Mantle5 shared keywordsMantle provides a data infrastructure layer that turns fragmented documents, reports, and records about alternative assets into structured, verified data for AI-powered workflows and decisions. It offers two platforms: Mantle Portal for private fund data and portfolio management (used by endowments, family offices, funds of funds, and pensions), and Mantle Equity for equity and cap-table management (used by founders, CFOs, and law firms).
Mammoth Biosciences5 shared keywordsMammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
Mustang Bio5 shared keywordsMustang Bio in-licenses and develops next-generation therapies aimed at treating patients, operating in the biotechnology and therapeutics sector.
Talus Bio5 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Mantle4 shared keywordsMantle operates an Ethereum layer-2 network using ZK proofs, along with a treasury and token-holder governed roadmap for on-chain products. It also runs the Mantle EcoFund, a $200M capital pool that backs projects in its ecosystem, with support from Mirana Ventures and Bybit for liquidity and DeFi-CeFi interoperability.
Companies competing with MantleBio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does MantleBio do?
- MantleBio provides a data management and analytics platform designed for biotech researchers and scientific teams. The platform integrates biological data, enables advanced bioinformatics analysis, and accelerates drug development and genomics research workflows.
- Who founded MantleBio?
- MantleBio was founded by Emily Damato, Madeline Schade in 2023.
- Who are MantleBio's investors?
- MantleBio's investors include Hawk Hill Ventures, Lobster Capital, The E14 Fund, Y Combinator.